Clinical Trial Detail

NCT ID NCT02340975
Title A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MedImmune LLC
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.